Primary Site >> Pancreatic Cancer
Gene >> RET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Genetic aspects of multiple endocrine neoplasia types 1 and 2. PMID: 7584011 |
Ref: Advances in molecular genetics. PMID: 9046882 |
Ref: Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). PMID: 10077155 |
Ref: Guidelines for diagnosis and therapy of MEN type 1 and type 2. PMID: 11739416 |
Ref: Activation of phosphatidylinositol 3-kinase and extracellular signal-regulated kinase is required for glial cell line-derived neurotrophic factor-induced migration and invasion of pancreatic carcinoma cells. PMID: 15289335 |
Ref: Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. PMID: 16269310 Ref: The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. PMID: 16357163 |
Ref: The neurotrophic factor artemin promotes pancreatic cancer invasion. PMID: 16858191 Ref: [Pathogenic patterns of genetic predisposition to endocrine tumors]. PMID: 17373213 |
Ref: Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene. PMID: 18299477 Ref: The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. PMID: 18652760 |
Ref: Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. PMID: 19017755 Ref: CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. PMID: 19057948 Ref: Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. PMID: 19903778 |
Ref: Paracrine regulation of pancreatic cancer cell invasion by peripheral nerves. PMID: 20068194 |
Ref: High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells. PMID: 20960036 Ref: CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma. PMID: 21177330 Ref: RET-protooncogene variants in patients with sporadic neoplasms of the digestive tract and the central nervous system. PMID: 21311890 |
Ref: The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma. PMID: 22189301 Ref: Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor. PMID: 22971345 |
Ref: Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers. PMID: 22973956 Ref: Systemic treatment for hereditary cancers: a 2012 update. PMID: 23548133 Ref: Medullary thyroid carcinoma and duodenal calcitonin-secreting neuroendocrine tumour: more than coincidence? PMID: 24616764 |
Ref: Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. PMID: 25197551 |
Ref: The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth. PMID: 25301453 Ref: Basaloid carcinoma of the pancreas--clinicopathological presentation and oncogenetic snapshot of a rare entity. PMID: 25432630 Ref: Identification of biomarkers for the prognosis of pancreatic ductal adenocarcinoma with miRNA microarray data. PMID: 25791160 |
Ref: Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. PMID: 26715573 Ref: The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. PMID: 26874741 Ref: Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. PMID: 27798861 |
Ref: Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma. PMID: 28092668 Ref: Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. PMID: 28259610 Ref: [Multiple endocrine neoplasia]. PMID: 28902384 |